Collectively, these findings position nitidine as a promising therapeutic strategy to enhance the efficacy of EGFR inhibitors and overcome osimertinib resistance in EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.